Selective Tumour-Targeting with Drug Conjugates

Evamarie Hey-Hawkins
Universität Leipzig, Fakultät für Chemie und Mineralogie, Institut für Anorganische Chemie, Johannisallee 29, 04103 Leipzig. hey@uni-leipzig.de

Cancer is among the leading causes of death worldwide. Chemotherapy, one of the most common treatments, is often accompanied by significant side effects, and tumour resistance to certain chemotherapeutic drugs is another major problem. Therefore, the search for new antitumour agents and new therapy methods is important.

The Hey-Hawkins group designs metal-based chemotherapeutic agents which, when combined with biologically active compounds or drugs already used in cancer therapy, have a higher selectivity and activity towards tumour cells (hybrid compounds, dual therapy).



References

I. Predarska, M. Saoud, I. Morgan, T. Eichhorn, G. N. Kaluđerović, E. Hey-Hawkins, Dalton Trans. **51** (2021) 857-869.

D. Drača, M. Marković, M. Gozzi, S. Mijatović, D. Maksimović-Ivanić, E. Hey-Hawkins, Molecules **26** (2021) 3801 (10 pages).

M. Gozzi, B. Murganić, D. Drača, J. Popp, P. Coburger, D. Maksimović-Ivanić, S. Mijatović, E. Hey-Hawkins, ChemMedChem **14** (2019) 2061-2074.

B. Schwarze, S. Jelača, L. Welcke, D. Maksimović-Ivanić, S. Mijatović, E. Hey-Hawkins, ChemMedChem **14** (2019) 2075-2083.

W. Neumann, B. C. Crews, M. B. Sárosi, C. M. Daniel, K. Ghebreselasie, M. S. Scholz, L. J. Marnett, E. Hey-Hawkins, ChemMedChem **10** (2015) 183-192.

W. Neumann, B. C. Crews, L. J. Marnett, E. Hey-Hawkins, ChemMedChem **9** (2014) 1150-1153.